Skip to main content

HomeMK-677Legal status

Educational — Not Legal AdviceReviewed

Is MK-677 legal? FDA status and US regulatory standing

Current status

Barred from compounding. MK-677 is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound (status recorded ).

Primary source: www.fda.gov

Federal legal status

FDA approval status

MK-677 is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound. Non-peptide ghrelin mimetic. Active IND; Phase 2/3 trials by Merck/Helsinn. Never FDA-approved. FDA enforcement actions against MK-677 supplements as unapproved new drug. Investigational only.

Also known as

Ibutamoren · MK-0677 · Nutrobal

Status history

  • MK-677 is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound. [source]

Frequently asked questions

Is MK-677 FDA approved?
MK-677 is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound (status recorded 2023-09-29). Primary source linked on this page.
Is MK-677 legal to buy?
MK-677 is available in the U.S. as a research-use-only compound. It is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound. Sale for human consumption is not permitted.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: Regulatory status is sourced from the linked primary records and reviewed by the PeptideBase editorial team. This page is educational — not legal or medical advice. Last reviewed: .

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.

Free Guide

The Peptide Research Digest

Get our free provider vetting guide — plus weekly research briefings on peptide sourcing, COA verification, and clinical developments.

No spam.